CROS NT Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • CROS NT's estimated annual revenue is currently $10.7M per year.(i)
  • CROS NT's estimated revenue per employee is $201,000

Employee Data

  • CROS NT has 53 Employees.(i)
  • CROS NT grew their employee count by 4% last year.

CROS NT's People

NameTitleEmail/Phone
1
Owner and Chairman/CEOReveal Email/Phone
2
Managing DirectorReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
Director Statistical ProgrammingReveal Email/Phone
5
Associate Director Statistical ProgrammingReveal Email/Phone
6
Corporate Social Responsibility ManagerReveal Email/Phone
7
Principal Statistical ProgrammerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7M3521%N/AN/A
#2
$3.2M160%N/AN/A
#3
$100.7M5017%N/AN/A
#4
$37.4M18655%N/AN/A
#5
$69.8M2780%$35MN/A
#6
$13.1M655%N/AN/A
#7
$8.2M41-7%N/AN/A
#8
$2.6M130%N/AN/A
#9
$165.7M22714%$250.7MN/A
#10
$27.9M139-10%$637.8KN/A
Add Company

What Is CROS NT?

Stat-Tech Services, LLC is a provider of statistical support services for pharmaceutical and medical device companies. The company has senior staff members with many years of statistical and programming experience. Stat-Tech Services, LLC is used to working closely with smaller companies and start-ups. We focus on being part of your team, not just providing you services. If you are looking for a team that will be committed to providing you the types of support you need, then please contact us.

keywords:N/A

N/A

Total Funding

53

Number of Employees

$10.7M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CROS NT News

2022-04-19 - Phase I – IV Clinical Development Services Market Analysis ...

... Thermo Fisher Scientific, LabCorp, Worldwide Clinical Trial, CROS NT, Dynakin, Rho, Inc., Synteract, ICBio CRO, Sofpromed, Profil,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$19.3M5333%N/A
#2
$7.5M5413%N/A
#3
$8.4M5454%N/A
#4
$12.2M542%N/A
#5
$13.4M55-5%N/A